Platelet gene polymorphisms and risk of bleeding in patients undergoing elective coronary angiography: A genetic substudy of the PRAGUE-8 trial

Atherosclerosis

Volumn 212, Issue 2, 2010, Pages 548-552

  Motovska, Zuzana ^a   Kvasnicka, Jan ^b   Hajkova, Jaroslava ^b   Kala, Petr ^c   Simek, Stanislav ^b   Bobcikova, Petra ^b   Petr, Robert ^a   Bilkova, Dana ^a   Poloczek, Martin ^c   Miklik, Roman ^c   Fischerova, Michaela ^a   Maly, Marek ^d   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Bleeding complications; Elective coronary angiography; Platelet polymorphisms; Single nucleotide polymorphism

Indexed keywords

ALANINE; ALPHA2 INTEGRIN; CLOPIDOGREL; CYCLOOXYGENASE 1; CYSTEINE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUORESCENT DYE; GLYCINE; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y12 RECEPTOR; THREONINE; THROMBOCYTE ENZYME; THROMBOCYTE RECEPTOR;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC PROCEDURE; ELECTIVE CORONARY ANGIOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELTING POINT; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE;

AGED; BLOOD PLATELETS; CATHETERIZATION; CORONARY ANGIOGRAPHY; FEMALE; GENOTYPE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK;

EID: 77957703701     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.006     Document Type: Article

References (45)

1. Cook S., Walter A., Hugli O., Togni M., Meier B. Percutaneous interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol 2007, 96:375-382.
2. Rosamond W., Flegal K., Furie K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117:e25-146.
3. Kinnaird T., Anderson R., Hill J., Thomas M. Bleeding during percutaneous intervention: tailoring the approach to minimise risk. Heart 2009, 95:15-19.
4. Feit F., Voeltz M.D., Attubato M.J., et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol 2007, 100:1364-1369.
5. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003, 24:1815-1823.
6. Widimsky P., Motovska Z., Simek S., et al. Clopidogrel pre-treatment in stable angina: for all patients >6h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008, 29(12):1495-1503.
7. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988, 11:1-11.
8. Kunicki T.J. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002, 22:14-20.
9. Welsby I.J., Podgoreanu M.V., Phillips-Bute B., et al. Genetic factors contribute to bleeding after cardiac surgery. J Thromb Haemost 2005, 3:1206-1212.
10. Schwinn D, Podgoreanu MV, Stafford-smith M, Newman MF. Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction. United States Patent 7439019, http://www.freepatentsonline.com/7439019.html.
11. Best D., Senis Y.A., Jarvis G.E., et al. GPVI levels in platelets: relationship to platelet function at high shear. Blood 2003, 102:2811-2818.
12. Iniesta J.A., Gonzalez-Conejero R., Piqueras C., Vicente V., Corral J. Platelet GP IIIa polymorphism HPA-1 (PlA) protects against subarachnoid hemorrhage. Stroke 2004, 35:2282-2286.
13. Dupont A., Fontana P., Bachelot-Loza C., et al. An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN. Blood 2003, 101:1833-1840.
14. Undas A., Brummel K., Musial J., Mann K.G., Szczeklik A. PlA2 polymorphism of β3 integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001, 104:2666-2672.
15. Jin J., Quinton T.M., Zhang J., Rittenhouse S.E., Kunapuli S.P. Adenosine diphosphate (ADP)-induced thromboxane A2 generation in human platelets requires coordinated signaling through integrin αIIbβ3 and ADP receptors. Blood 2002, 99:193-198.
16. Halushka M.K., Walker L.P., Halushka P.V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003, 73(1):122-130.
17. Kvasnicka J., Hajkova J., Bobcikova P., et al. Platelet gene polymorphisms related to atherothrombogenesis and their frequencies in a healthy Czech population of middle age. CorVasa 2009, 51(3):1-7.
18. Davidge S.T. Prostaglandin H synthase and vascular function. Circ Res 2001, 89:650-660.
19. FitzGerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B.
20. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J Lipid Res 2009, 50:S423-S428.
21. The National Institutes of Health (NIH). The Single Nucleotide Polymorphism database (dbSNP) a public-domain archive for a broad collection of simple genetic polymorphisms. http://www.ncbi.nlm.nih.gov/SNP.
22. Dargaud Y., Bordet J.C., Trzeciak M.C., et al. Inherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiency. Thromb Res 2005, 116:483-489.
23. Maree A.O., Fitzgerald D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007, 115:2196-2307.
24. Maree A.O., Curtin R.J., Chubb A., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005, 3:2340-2345.
25. Hillarp A., Palmqvist B., Lethagen S., Villoutreix B.O., Mattiasson I. Mutation within the cyclooxgenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003, 112:275-283.
26. Clappers N., van Oijen M.G., Sundaresan S., et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008, 100:70-75.
27. Lee C.R., Bottone F.G., Krahn J.M., et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 2007, 17:145-160.
28. Helmersson J., Ärnlöv J., Axelsson T., Basu S. A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2a formation and lower risk of cardiovascular disease. Prostaglandins, Leukotrienes Essential Fatty Acids 2009, 80:51-56.
29. Iglehart J.K. The new era of medical imaging-progress and pitfalls. N Engl J Med 2006, 354:2822-2828.
30. Togni M., Balmer F., Pfiffner D., et al. Percutaneous coronary interventions in Europe 1992-2001. Eur Heart J 2004, 25:1208-1213.
31. Hobbs M.S.T., McCaul K.A., Knuiman M.W., Rankin J.M., Gilfillan I. Trends in coronary artery revascularisation procedures in Western Australia, 1980-2001. Heart 2004, 90:1036-1041.
32. Gao R.L. Current status and perspective of percutaneous coronary intervention in China. Chin Med J 2006, 119(7):531-532.
33. Alter D.A., Newman A., Stukel T.A. Proliferation of cardiac technology in Canada: a challenge to the sustainability of Medicare. Circulation 2006, 113:380-387.
34. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on coronary angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999, 33:1756-1824.
35. Hemingway H., Crook A.M., Banarjee S., et al. Hypothetical ratings of coronary angiography appropriateness: are they associated with actual angiographic findings, mortality, and revascularisation rates. The ACRE study. Heart 2001, 85:672-679.
36. Brause M., Grande G., Mannebach H., Badura B. The impact of social and institutional characteristics on the appropriateness of invasive cardiologic procedures. Med Klin (Munich) 2006, 101(3):226-234.
37. Schilling J., Gerstl P., Kapetanios E., Lee C.Y., Bertel O. Assessment of indications in interventional cardiology: appropriateness and necessity of coronary angiography and revascularization. Am J Med Qual 2003, 18:155-163.
38. Sibai A.M., Tohme R.A., Saade G.A., et al. The appropriateness of use of coronary angiography in Lebanon: implications for health policy. Health Policy Plan 2008, 23(3):210-217.
39. Gontijo R.V., Proietti F.A., Amaral C.F., de Rezende N.A. Appropriateness use of coronary angiography in patients with suspected ischemic heart disease in Brazil. Int J Cardiol 2005, 104:348-349.
40. Kinnaird T.D., Stabile E., Mintz G.S., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003, 92:930-935.
41. Lauer M.A., Karweit J.A., Cascade E.F., Lin N.D., Topol E.J. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. Am J Cardiol 2002, 89:924-929.
42. Milkovich G., Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003, 60(Suppl 3):S15-S21.
43. Husmann L., Herzog B.A., Gaemperli O., et al. Diagnostic accuracy of computed tomography coronary angiography and evaluation of stress-only single-photon emission computed tomography/computed tomography hybrid imaging: comparison of prospective electrocardiogram-triggering vs. retrospective gating. Eur Heart J 2009, 30(5):600-607.
44. Agostoni P., Biondi-Zoccai G.G., de Benedictis M.L., et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004, 44(July (2)):349-356.
45. Boden W.E., O'Rourke R.A., Teo K.K., et al. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol 2009, 104(1):1-4.